Ten Bio News
A season of global engagement in skin science and innovation
This spring, Ten Bio joined leading voices in dermatology at events in France, the US, and Australia—spotlighting TenSkin™ as a powerful, human-relevant alternative to animal testing. From photoprotection to microneedle delivery, the message was clear: innovation needs better models.
Ten Bio joins James Hutton Institute’s Dundee campus to advance dermatological research
Ten Bio has officially joined the James Hutton Institute’s Dundee campus, marking a new chapter in its mission to advance human-relevant dermatology research. The move supports Ten Bio’s continued growth and fosters collaboration with one of Scotland’s leading scientific communities.
Predicting human response to gene-based therapies in preclinical evaluation
Why do so many gene therapies fail in clinical trials? A closer look at the preclinical gap—and how TenSkin™ is helping close it.
Beyond animal models: The future of skin testing is human-relevant and ready
As regulatory momentum builds and new human-relevant technologies emerge, the conversation is shifting. The question is no longer if we can replace animal testing in skin research — but how fast. This article explores why models like TenSkin™ offer a scalable, scientifically robust alternative that’s already reshaping preclinical research.
Setting the standard: How TenSkin is shaping regulatory change in skin testing
As regulators move away from animal testing, clear validation frameworks are needed to support alternatives. Explant models like TenSkin™ offer a human-relevant solution for preclinical skin research, improving predictability and reproducibility.
Pollution protection
Urban pollution drives demand for advanced skincare. Ten Bio’s TenSkin™ offers a next generation ex vivo model to test anti-pollution products, providing crucial insights that accelerate the development of scientifically validated, high-impact solutions.
Happy Holidays 2024
Spreading Holiday cheer – from the Ten Bio team to all of our clients, collaborators and partners – past, present and future! As the year winds down, we want to take a moment to express a heartfelt thank you for being a part of our journey through 2024.
The advantages of extended viability in TenSkin™ for dermatological research
Ten Bio’s TenSkin™ ex vivo human skin model offers two-week viability, enhancing the depth and reliability of skin studies, allowing for more detailed insights into skin health and treatment efficacy.
A tensioned human skin explant model used for preliminary assessment of chemexfoliant-stimulated bioeffects
Our latest study, using the TenSkinᵀᴹ model, demonstrates how our ex vivo platform is delivering biologically relevant insights into the effects of chemexfoliation (chemical peel) treatments on human skin.
Ten Bio shortlisted for The Courier Business Awards
We are proud to be announced as finalist in The Courier Business Awards in the Innovation and Technology category.
Ten Bio named finalist in Scotland’s Life Science award.
Ten Bio is proud to announce that our company has been named one of three finalists in Scotland’s Life Science award in the category ‘Innovation
The origins of TenSkin™
Entering our third year since spin out, it’s time to celebrate the origins of our technology which has brought Ten Bio early success in a
‘When I was two, I was nearly new’ ….
‘When I was two I was nearly new’ … with thanks to A. A. Milne for the line from his 1927 poem ‘Now we are
Our differentiation in wound management….
In the previous note from the chairman I emphasized the potential role for Ten Bio in the area of wound management. My reason for that
Dr Paul Campbell seconded to Ten Bio through UK Medical Research Council Innovation Scholarship
Dr Paul Campbell, Reader in Physics at the University of Dundee has recently begun a secondment to Ten Bio through an Innovation Scholarship funded by the UK’s Medical Research Council.